| Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes A Nazha, K Al-Issa, BK Hamilton, T Radivoyevitch, AT Gerds, S Mukherjee, ... Leukemia 31 (12), 2848-2850, 2017 | 64 | 2017 |
| Management and outcome of patients with Langerhans cell histiocytosis and single‐bone CNS‐risk lesions: a multi‐institutional retrospective study D Chellapandian, F Shaikh, C van den Bos, GR Somers, I Astigarraga, ... Pediatric blood & cancer 62 (12), 2162-2166, 2015 | 30 | 2015 |
| BCOR and BCORL1 mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes N Abuhadra, S Mukherjee, K Al-Issa, V Adema, CM Hirsch, A Advani, ... Leukemia & lymphoma 60 (6), 1587-1590, 2019 | 22 | 2019 |
| Epilepsy in Qatar: causes, treatment, and outcome N Haddad, G Melikyan, H Al Hail, A Al Jurdi, F Aqeel, A Elzafarany, ... Epilepsy & Behavior 63, 98-102, 2016 | 22 | 2016 |
| Beyond HER2: targeting the ErbB receptor family in breast cancer JZ Drago, E Ferraro, N Abuhadra, S Modi Cancer treatment reviews 109, 102436, 2022 | 20 | 2022 |
| Impact of TP53 mutations in triple negative breast cancer ZI Mitri, N Abuhadra, SM Goodyear, EA Hobbs, A Kaempf, AM Thompson, ... npj Precision Oncology 6 (1), 64, 2022 | 15 | 2022 |
| Molecular characterization and prospective evaluation of pathologic response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer C Yam, N Abuhadra, R Sun, BE Adrada, QQ Ding, JB White, ... Clinical Cancer Research 28 (13), 2878-2889, 2022 | 15 | 2022 |
| Impact of social media for the hematologist/oncologist N Abuhadra, NS Majhail, A Nazha Seminars in Hematology 54 (4), 193-197, 2017 | 15 | 2017 |
| Early-stage triple-negative breast cancer: time to optimize personalized strategies N Abuhadra, S Stecklein, P Sharma, S Moulder The oncologist 27 (1), 30-39, 2022 | 13 | 2022 |
| BI-RADS ultrasound lexicon descriptors and stromal tumor-infiltrating lymphocytes in triple-negative breast cancer RP Candelaria, DA Spak, GM Rauch, L Huo, RL Bassett, L Santiago, ... Academic radiology 29, S35-S41, 2022 | 11 | 2022 |
| Differences in genomic patterns and clinical outcomes between African-American and White patients with myelodysplastic syndromes A Nazha, K Al-Issa, B Przychodzen, N Abuhadra, C Hirsch, ... Blood Cancer Journal 7 (9), e602-e602, 2017 | 9 | 2017 |
| Molecularly targeted therapies for triple negative breast cancer: history, advances, and future directions N Mai, N Abuhadra, K Jhaveri Clinical Breast Cancer, 2023 | 7 | 2023 |
| A personalized prediction model to risk stratify patients with myelodysplastic syndromes (MDS) A Nazha, RS Komrokji, J Barnard, K Al-Issa, E Padron, YF Madanat, ... Blood 130, 160, 2017 | 7 | 2017 |
| BCOR Mutations in Myelodysplastic Syndromes (MDS): Mutation Characteristics Impact Clinical Outcomes N Abuhadra, K Al-Issa, S Mukherjee, CM Hirsch, AT Gerds, BK Jha, ... Blood, The Journal of the American Society of Hematology 130 (Suppl_1), 5304 …, 2017 | 6 | 2017 |
| Prognostic impact of high baseline stromal tumor-infiltrating lymphocytes in the absence of pathologic complete response in early-stage triple-negative breast cancer N Abuhadra, R Sun, JK Litton, GM Rauch, C Yam, JT Chang, S Seth, ... Cancers 14 (5), 1323, 2022 | 5 | 2022 |
| Beyond TILs: Predictors of pathologic complete response (pCR) in triple-negative breast cancer (TNBC) patients with moderate tumor-infiltrating lymphocytes (TIL) receiving … N Abuhadra, KR Hess, JK Litton, GM Rauch, AM Thompson, B Lim, ... Journal of Clinical Oncology 37 (15_suppl), 572-572, 2019 | 4 | 2019 |
| Model heterogeneity in predicting outcomes of patients with myelodysplastic syndromes (MDS) K Al-Issa, YF Madanat, S Mukherjee, CM Hirsch, AT Gerds, N Abuhadra, ... Blood 130, 2972, 2017 | 4 | 2017 |
| Mutational signatures associated with intensity and duration of smoking in Myelodysplastic Syndromes (MDS) YF Madanat, T Radivoyevitch, A Nazha, Y Sawalha, K Al-Issa, ... Blood 130, 424, 2017 | 3 | 2017 |
| Predictive roles of baseline stromal tumor-infiltrating lymphocytes and ki-67 in pathologic complete response in an early-stage triple-negative breast cancer prospective trial N Abuhadra, R Sun, C Yam, GM Rauch, Q Ding, B Lim, AM Thompson, ... Cancers 15 (13), 3275, 2023 | 2 | 2023 |
| Prognostic impact of high stromal tumor-infiltrating lymphocytes (sTIL) in the absence of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in early stage triple … N Abuhadra, R Sun, JK Litton, GM Rauch, AM Thompson, B Lim, ... Journal of Clinical Oncology 38 (15_suppl), 583-583, 2020 | 2 | 2020 |
